Back to search results

Pain Management for Testicular Cancer Surgery

This study is comparing two standard pain medications, intrathecal morphine and intravenous methadone, for managing pain after surgery for testicular cancer. Doctors want to see which one works better at reducing the amount of pain medication you need in the first 24 hours after surgery. You might be able to join if you are a man between 18 and 80 years old, having your first or post-chemotherapy retroperitoneal lymph node dissection (a surgery to remove lymph nodes in your abdomen) for testicular cancer. The study is looking for 142 participants, but its current status is unclear.

Study design
This is a randomized study, meaning you would be randomly assigned to receive either intrathecal morphine or intravenous methadone. It is a single-blinded study, so you wouldn't know which treatment you're receiving, but the doctors would. The study plans to enroll 142 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, opioid consumption, is measured during the first 24 hours after surgery. Further follow-up beyond this time is not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06593665

Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.

Recruiting
PHASE3Ages 18–80Interventional
Indiana University
~142 participants
Updated 2026-02-13 on ClinicalTrials.gov
What's tested:Inrathecal MorphineIntravenous Methadone

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
IV morphine equivalent (MME)
Measured over First 24 hours postoperative

Conditions

Testicular Cancer

Explore related trials

Malignant Testicular Neoplasm

Where it's being run

2 sites across 1 states
Indiana2

Study leadership

  • Gulraj S Chawla, MD · PRINCIPAL_INVESTIGATOR · Indiana University

Who to contact

Lyla S Farlow
[email protected]
3179489804
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients undergoing a virgin (chemotherapy has not been used) or post- chemotherapy retroperitoneal lymph node dissection for primary testicular cancer at IU Health AAHC
ASA Class 1, 2, 3
Age 18 to 80 years; Male
BMI less than 50kg/m2

Exclusion

Any contraindication for neuraxial analgesia
Patient on home methadone at any dose
Any physical, mental or medical conditions which, in the opinion of the investigators, may confound quantifying postoperative pain resulting from surgery.
Known true allergy to the study medications (morphine, bupivacaine, acetaminophen, methadone)
Any history of substance abuse in the past 6 months which would include heroin or any other illegal street drugs
End stage liver disease, end stage renal disease
Patient staying intubated after surgery
Patient (home dose) taking more than 30mg PO morphine equivalent (PME) per day
Any additional surgical procedures to the patient with a different surgical incision compared to the standard laparotomy for the RPLND procedure, i.e. thoracic tumor reduction

What this trial measures

  • IV morphine equivalent (MME)First 24 hours postoperative

    Cumulative Milligrams of morphine equivalent (MME) consumption